{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:06:25Z","timestamp":1790967985839,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Certara Strategic Consulting"},{"DOI":"10.13039\/100014481","name":"Kite Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014481","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40262-024-01413-z","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T15:03:14Z","timestamp":1725634994000},"page":"1283-1299","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Investigating the Influence of Covariates on Axicabtagene Ciloleucel (axi-cel) Kinetics in Patients with Non-Hodgkin\u2019s Lymphoma"],"prefix":"10.1007","volume":"63","clinical-trial-number":[{"clinical-trial-number":"nct02348216","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03105336","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03391466","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7659-8764","authenticated-orcid":false,"given":"Magali","family":"Chartier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Filosto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Peyret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Chiney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Milletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Budka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Ndi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghui","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saran","family":"Vardhanabhuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daqin","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Duffull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dodds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhine","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,6]]},"reference":[{"key":"1413_CR1","unstructured":"US FDA. US prescribing information: Yescarta (axicabtagene ciloleucel). Santa Monica (CA): Kite Pharma, Inc; 2022. Available from: https:\/\/www.fda.gov\/media\/108377\/download. Accessed 31 Jan 2023."},{"key":"1413_CR2","first-page":"878","volume":"10","author":"AC King","year":"2019","unstructured":"King AC, Orozco JS. Axicabtagene ciloleucel: the first FDA-approved CAR T-cell therapy for relapsed\/refractory large B-cell lymphoma. J Adv Pract Oncol. 2019;10:878\u201382.","journal-title":"J Adv Pract Oncol"},{"key":"1413_CR3","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/ajh.26301","volume":"96","author":"JR Westin","year":"2021","unstructured":"Westin JR, Kersten MJ, Salles G, Abramson JS, Schuster SJ, Locke FL, et al. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed\/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials. Am J Hematol. 2021;96:1295\u2013312.","journal-title":"Am J Hematol"},{"key":"1413_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/2162-3619-1-36","volume":"1","author":"K Wang","year":"2012","unstructured":"Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012;1:36.","journal-title":"Exp Hematol Oncol"},{"key":"1413_CR5","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain M, Brentjens R, Rivi\u00e8re I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3:388\u201398.","journal-title":"Cancer Discov"},{"key":"1413_CR6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","volume":"25","author":"FL Locke","year":"2017","unstructured":"Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 Anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther J Am Soc Gene Ther. 2017;25:285\u201395.","journal-title":"Mol Ther J Am Soc Gene Ther."},{"key":"1413_CR7","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531\u201344.","journal-title":"N Engl J Med"},{"key":"1413_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","volume":"23","author":"CA Jacobson","year":"2022","unstructured":"Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23:91\u2013103.","journal-title":"Lancet Oncol"},{"key":"1413_CR9","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA, Perales M-A, Kersten M-J, Oluwole OO, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386:640\u201354.","journal-title":"N Engl J Med"},{"key":"1413_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20:31\u201342.","journal-title":"Lancet Oncol"},{"key":"1413_CR11","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, et al. 5-Year follow-up supports curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1). Blood. 2023; p. blood.2022018893.","DOI":"10.1182\/blood.2022018893"},{"key":"1413_CR12","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1056\/NEJMoa2301665","volume":"389","author":"JR Westin","year":"2023","unstructured":"Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales M-A, Ghobadi A, et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med. 2023;389:148\u201357.","journal-title":"N Engl J Med"},{"key":"1413_CR13","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188\u201395.","journal-title":"Blood"},{"key":"1413_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69.","journal-title":"Blood Cancer J"},{"key":"1413_CR15","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1007\/s00415-020-10237-3","volume":"268","author":"EC Tallantyre","year":"2021","unstructured":"Tallantyre EC, Evans NA, Parry-Jones J, Morgan MPG, Jones CH, Ingram W. Neurological updates: neurological complications of CAR-T therapy. J Neurol. 2021;268:1544\u201354.","journal-title":"J Neurol"},{"key":"1413_CR16","unstructured":"US Food and Drug Administration. Center for Biologics Evaluation and Research. Considerations for the development of chimeric antigen receptor (CAR) T cell products. Draft guidance for industry. 2022. Available from: https:\/\/www.fda.gov\/media\/156896\/download. Accessed 2 Jul 2023."},{"key":"1413_CR17","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on safety and efficacy follow-up and risk management of advanced therapy medicinal products. EMEA\/149995\/2008 rev.1.; 2018. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-guideline-safety-efficacy-follow-risk-management-advanced-therapy-medicinal-products-revision_en.pdf. Accessed 2 Jul 2023."},{"key":"1413_CR18","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","volume":"4","author":"FL Locke","year":"2020","unstructured":"Locke FL, Rossi JM, Neelapu SS, Jacobson CA, Miklos DB, Ghobadi A, et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020;4:4898\u2013911.","journal-title":"Blood Adv"},{"key":"1413_CR19","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/A:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28:481\u2013504.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1413_CR20","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","volume":"11","author":"RM Savic","year":"2009","unstructured":"Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J. 2009;11:558\u201369.","journal-title":"AAPS J"},{"key":"1413_CR21","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579\u201386.","journal-title":"J Clin Oncol"},{"key":"1413_CR22","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1182\/blood.2020008865","volume":"137","author":"P Strati","year":"2021","unstructured":"Strati P, Ahmed S, Furqan F, Fayad LE, Lee HJ, Iyer SP, et al. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Blood. 2021;137:3272\u20136.","journal-title":"Blood"},{"key":"1413_CR23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/psp4.12161","volume":"6","author":"THT Nguyen","year":"2017","unstructured":"Nguyen THT, Mouksassi M-S, Holford N, Al-Huniti N, Freedman I, Hooker AC, et al. Model evaluation of continuous data pharmacometric models: metrics and graphics. CPT Pharmacomet Syst Pharmacol. 2017;6:87\u2013109.","journal-title":"CPT Pharmacomet Syst Pharmacol."},{"key":"1413_CR24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13:143\u201351.","journal-title":"AAPS J"},{"key":"1413_CR25","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s40262-021-01039-5","volume":"60","author":"K Ogasawara","year":"2021","unstructured":"Ogasawara K, Dodds M, Mack T, Lymp J, Dell\u2019Aringa J, Smith J. Population cellular kinetics of lisocabtagene maraleucel, an autologous CD19-directed chimeric antigen receptor T-cell product, in patients with Rrlapsed\/refractory large B-cell lymphoma. Clin Pharmacokinet. 2021;60:1621\u201333.","journal-title":"Clin Pharmacokinet"},{"key":"1413_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jtbi.2012.12.025","volume":"327","author":"RJ De Boer","year":"2013","unstructured":"De Boer RJ, Perelson AS. Quantifying T lymphocyte turnover. J Theor Biol. 2013;327:45\u201387.","journal-title":"J Theor Biol"},{"key":"1413_CR27","doi-asserted-by":"publisher","first-page":"1688616","DOI":"10.1080\/19420862.2019.1688616","volume":"12","author":"AP Singh","year":"2020","unstructured":"Singh AP, Zheng X, Lin-Schmidt X, Chen W, Carpenter TJ, Zong A, et al. Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model. MAbs. 2020;12:1688616.","journal-title":"MAbs"},{"key":"1413_CR28","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316.","journal-title":"N Engl J Med"},{"key":"1413_CR29","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/psp4.12388","volume":"8","author":"AM Stein","year":"2019","unstructured":"Stein AM, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, Boyer MW, et al. Tisagenlecleucel model-based cellular kinetic analysis of chimeric antigen receptor-T cells. CPT Pharmacomet Syst Pharmacol. 2019;8:285\u201395.","journal-title":"CPT Pharmacomet Syst Pharmacol."},{"key":"1413_CR30","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382:1331\u201342.","journal-title":"N Engl J Med"},{"key":"1413_CR31","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/cpt.2040","volume":"109","author":"C Liu","year":"2021","unstructured":"Liu C, Ayyar VS, Zheng X, Chen W, Zheng S, Mody H, et al. Model-based cellular kinetic analysis of chimeric antigen receptor-T cells in humans. Clin Pharmacol Ther. 2021;109:716\u201327.","journal-title":"Clin Pharmacol Ther"},{"key":"1413_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.803693","volume":"13","author":"W Mu","year":"2022","unstructured":"Mu W, Long X, Cai H, Chen C, Hu G, Lou Y, et al. A model perspective explanation of the long-term sustainability of a fully human BCMA-targeting CAR (CT103A) T-cell immunotherapy. Front Pharmacol. 2022;13: 803693.","journal-title":"Front Pharmacol"},{"key":"1413_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.664421","volume":"11","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Li J, Lou X, Chen X, Yu Z, Kang L, et al. A prospective investigation of bispecific CD19\/22 CAR T cell therapy in patients with relapsed or refractory B cell non-Hodgkin lymphoma. Front Oncol. 2021;11: 664421.","journal-title":"Front Oncol"},{"key":"1413_CR34","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1182\/bloodadvances.2019000525","volume":"4","author":"R Awasthi","year":"2020","unstructured":"Awasthi R, Pacaud L, Waldron E, Tam CS, J\u00e4ger U, Borchmann P, et al. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed\/refractory DLBCL. Blood Adv. 2020;4:560\u201372.","journal-title":"Blood Adv"},{"key":"1413_CR35","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1111\/cts.13421","volume":"15","author":"LS Wu","year":"2022","unstructured":"Wu LS, Su Y, Li C, Zhou W, Jackson CC, Sun Y-N, et al. Population-based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myeloma. Clin Transl Sci. 2022;15:3000\u201311.","journal-title":"Clin Transl Sci"},{"key":"1413_CR36","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3389\/fphar.2020.00406","volume":"11","author":"JH Ahmed","year":"2020","unstructured":"Ahmed JH, Makonnen E, Bisaso RK, Mukonzo JK, Fotoohi A, Aseffa A, et al. Population pharmacokinetic, pharmacogenetic, and pharmacodynamic analysis of cyclophosphamide in Ethiopian breast cancer patients. Front Pharmacol. 2020;11:406.","journal-title":"Front Pharmacol"},{"key":"1413_CR37","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/bmt.2017.79","volume":"52","author":"E Mohanan","year":"2017","unstructured":"Mohanan E, Panetta JC, Lakshmi KM, Edison ES, Korula A, Fouzia NA, et al. Population pharmacokinetics of fludarabine in patients with aplastic anemia and Fanconi anemia undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2017;52:977\u201383.","journal-title":"Bone Marrow Transplant"},{"key":"1413_CR38","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1182\/bloodadvances.2021006418","volume":"6","author":"VA Fabrizio","year":"2022","unstructured":"Fabrizio VA, Boelens JJ, Mauguen A, Baggott C, Prabhu S, Egeler E, et al. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Adv. 2022;6:1961\u20138.","journal-title":"Blood Adv"},{"key":"1413_CR39","doi-asserted-by":"publisher","first-page":"4452","DOI":"10.3390\/cancers14184452","volume":"14","author":"Q Liu","year":"2022","unstructured":"Liu Q, Liu Z, Wan R, Huang W. Clinical strategies for enhancing the efficacy of CAR T-cell therapy for hematological malignancies. Cancers. 2022;14:4452.","journal-title":"Cancers"},{"key":"1413_CR40","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19\u201328z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6:224ra25.","journal-title":"Sci Transl Med."},{"key":"1413_CR41","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839\u201352.","journal-title":"Lancet"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01413-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-024-01413-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01413-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T05:06:20Z","timestamp":1727931980000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-024-01413-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1413"],"URL":"https:\/\/doi.org\/10.1007\/s40262-024-01413-z","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"9 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Magali Chartier, Thomas Peyret, Andre Ndi, Michael Dodds, and Stephen Duffull are paid consultants of Certara. Manoj Chiney, Francesca Milletti, Justin Budka, Jinghui Dong, Saran Vardhanabhuti, Daqin Mao, Rhine Shen, and Simone Filosto are employees of Kite Pharma. This research was funded by Kite Pharma, Santa Monica, CA, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Stephen Duffull is an Editorial Board member of <i>Clinical Pharmacokinetics<\/i>, and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Simone Filosto, Francesca Milletti, Justin Budka, Jinghui Dong, Saran Vardhanabhuti; Daqin Mao Saran Vardhanabhuti; Daqin Mao, and Rhine Shen are employees of Kite, A Gilead Company. Manoj Chiney is employee of Gilead Sciences. Magali Chartier, Thomas Peyret, Stephen Duffull, Michael Dodds and Andre Ndi are employees of Certara.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"All studies were conducted in accordance with the 1964 Declaration of Helsinki, the general principles stated in the International Ethical Guidelines for Biomedical Research Involving Human Patients, guidelines for Good Clinical Practice as well as with applicable national or regional regulatory requirements. The trials were registered under the numbers NCT02348216, NCT03105336, and NCT03391466.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All patients analyzed in this study provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All authors provided consent for publication.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All data used in the analysis were obtained from Kite, a Gilead Company. Gilead Sciences shares anonymized individual patient data upon request or as required by law or regulation with qualified external researchers based on submitted curriculum vitae and reflecting no conflict of interest. The request proposal must also include a statistician. Approval of such requests is at Gilead Science\u2019s discretion and is dependent on the nature of the request, the merit of the research proposed, the availability of the data, and the intended use of the data. Data requests should be sent to datarequest@gilead.com.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The final model code is provided in the supplementary material.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"MC, TP, AN, MD, and SD contributed to the study conception and design of the population pharmacokinetic modeling. SF, RS, MC, FM, JB, JD, SV, and DM, contributed to the conception and design of the clinical trials. The population pharmacokinetic analysis was performed by MC and supervised by TP and MD. The dataset construction was performed by AN. The manuscript was written by MC. All authors reviewed and edited the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}